Loading...
•
Dec 31, 2019
Rockwell Medical Q4 2019 Earnings Report
Reported positive adoption trends for Dialysate Triferic, highlighted by a 77% increase in clinics under contract, and signed a contract with a Medium-Sized Dialysis Organization (MDO) for Dialysate Triferic purchase, providing access to up to 160 clinics. Also, entered into exclusive license and supply agreements with Sun Pharma for Triferic commercialization rights in India.
Key Takeaways
Rockwell Medical reported a net loss of $7.3 million on net sales of $15.5 million for the fourth quarter of 2019. The company saw a decrease in net sales compared to the same period in 2018, but also a reduction in general and administrative expenses.
Net loss for Q4 2019 was $7.3 million, an improvement compared to a net loss of $9.4 million in Q4 2018.
Net sales for Q4 2019 were $15.5 million, a decrease from $16.9 million in Q4 2018.
Gross profit for Q4 2019 was approximately $1.1 million, compared to $1.2 million for Q4 2018.
Selling and marketing expenses increased by $1.6 million due to investments in the commercial platform for Triferic launch.
Rockwell Medical
Rockwell Medical
Forward Guidance
Rockwell Medical expects adoption rates to accelerate through 2020 with the execution of sales, marketing, and medical education initiatives.